Understanding Your Diagnosis: Adult-Onset Immunodeficiency (AOID)
At a Glance
Adult-Onset Immunodeficiency (AOID) is a rare, non-contagious autoimmune condition where autoantibodies block a crucial immune signal called interferon-gamma. Though it mimics HIV by causing opportunistic infections, it is treatable with targeted therapies that fight infections and reset the immune system.
If you have been diagnosed with Adult-Onset Immunodeficiency (AOID) with anti-interferon-gamma autoantibodies, you may feel overwhelmed by a name that sounds complex and a condition that feels mysterious. It is common to feel a sense of “medical whiplash” because this condition can cause the same types of infections seen in people with advanced HIV, yet you are HIV-negative [1][2].
The first and most important thing to know is that this is an acquired condition, not something you were born with, and it is not contagious [3][4]. You did not “catch” this from anyone, and you cannot pass it to others. It is a specific type of immune system “glitch” where your body mistakenly attacks its own defenses.
Furthermore, the opportunistic infections themselves (like nontuberculous mycobacteria) are typically acquired from the environment and are generally not contagious from person-to-person [2]. You do not need to fear being a danger to your partner or children when you are actively fighting these germs, though standard good hygiene is always encouraged.
Understanding the Name
The medical name describes exactly what is happening in your body:
- Adult-Onset Immunodeficiency: This means your immune system was working normally for most of your life, but it began to struggle during adulthood, often starting in your 40s or 50s [5].
- Anti-Interferon-Gamma Autoantibodies: Interferon-gamma (IFN-γ) is a critical protein your immune system uses as a “signal” to tell your cells to kill certain types of bacteria and fungi [6]. An autoantibody is an antibody your body makes that mistakenly attacks your own tissues or proteins. In this case, your body produces antibodies that “neutralize” or block that vital signal, leaving you vulnerable to specific germs [7][8].
Why It Mimics HIV
Doctors sometimes refer to this condition as an “HIV mimic” because the lack of working interferon-gamma leads to opportunistic infections [3]. These are germs—like Nontuberculous Mycobacteria (NTM), certain fungi, or Salmonella—that a healthy immune system usually handles easily but can become severe or widespread when your defenses are down [9]. Unlike HIV, which destroys immune cells (T-cells), AOID leaves your cells intact but “mutes” the signal they need to work properly [8].
Who Does This Affect?
While this condition can affect anyone, researchers have found a strong link to people of Asian descent, particularly those from Southeast Asia or Southern China [10][11]. This is often due to a genetic predisposition, specifically certain markers like the HLA-DRB1*16:02 allele, which make it more likely for the body to develop these specific autoantibodies [12][10].
Stabilizing Facts
It is natural to feel anxious after a rare diagnosis, but understanding the nature of AOID can help ground you:
- It is manageable: While it is a chronic condition, it can be treated using a dual approach: long-term medications to fight infections and immunomodulators (like rituximab) to help “reset” the immune system by reducing the production of the harmful autoantibodies [4].
- It is a recognized condition: Though rare, specialists in immunology and infectious disease are familiar with how to test for and treat this syndrome [13].
- You are not alone in this: Many patients with this condition also have other autoimmune markers, such as those for thyroid disease or lupus, and your care team will likely monitor your overall health closely [5].
Your journey involves learning to navigate a “new normal” with your immune system. By working closely with specialists, you can create a plan to manage infections and address the underlying autoimmune cause. Check out the following pages to learn more:
Signs and Symptoms: Why Your Body Struggles to Fight Back
Learn about Adult-Onset Immunodeficiency (AOID) symptoms, including recurrent opportunistic infections like NTM, Sweet's syndrome, and why treatments fail.
The Molecular Map: How AOID Disarms the Immune System
Learn how Adult-Onset Immunodeficiency (AOID) affects your immune system. Understand anti-IFN-gamma autoantibodies, STAT1 tests, and mNGS lab results.
The Dual Approach: Treating Infection and Resetting the Immune System
Learn about the dual treatment approach for Adult-Onset Immunodeficiency (AOID). Understand how antimicrobial therapy and rituximab work together to heal you.
Survivorship: Managing Your Health for the Long Term
Learn how to manage adult-onset immunodeficiency (AOID) long-term. Understand vaccine safety, infection prevention, and what red-flag symptoms to watch for.
Common questions in this guide
Is Adult-Onset Immunodeficiency (AOID) contagious?
Why do doctors call AOID an "HIV mimic"?
What are anti-interferon-gamma autoantibodies?
Does genetics play a role in developing AOID?
How is Adult-Onset Immunodeficiency treated?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my symptoms and history, what specific tests (like an ELISA or a functional assay) were used to confirm the presence of anti-interferon-gamma autoantibodies?
- 2.Do I have any of the genetic markers, such as HLA-DRB1*16:02, that are commonly associated with this condition?
- 3.Since this condition mimics some aspects of HIV, are there specific 'opportunistic' infections we should be screening for regularly?
- 4.Will my treatment plan include both medications to fight current infections and medications (like rituximab) to address the autoantibodies themselves?
- 5.Are there other autoimmune conditions, like thyroid issues or lupus, that I should be monitored for?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (13)
- 1
Clinical Characteristics Analysis of 30 Cases of Interferon-γ Autoantibody-Positive Patients with Concurrent Mycobacterial Infection: A 6-Year Retrospective Study.
Zhao CY, Song C, He HW, et al.
Infection and drug resistance 2025; (18()):1097-1110 doi:10.2147/IDR.S493956.
PMID: 40027921 - 2
Multiple intracellular pathogen infections with ocular pathologies associated with adult-onset immunodeficiency due to anti-interferon-γ autoantibodies: a case report.
Ning Y, Yu Q, Liang H, et al.
BMC infectious diseases 2024; (24(1)):78 doi:10.1186/s12879-024-09003-x.
PMID: 38216890 - 3
Anti-Interferon Autoantibodies in Adult-Onset Immunodeficiency Syndrome and Severe COVID-19 Infection.
Chen LF, Yang CD, Cheng XB
Frontiers in immunology 2021; (12()):788368 doi:10.3389/fimmu.2021.788368.
PMID: 35003106 - 4
Simultaneous disseminated infections with intracellular pathogens: an intriguing case report of adult-onset immunodeficiency with anti-interferon-gamma autoantibodies.
Roerden M, Döffinger R, Barcenas-Morales G, et al.
BMC infectious diseases 2020; (20(1)):828 doi:10.1186/s12879-020-05553-y.
PMID: 33176707 - 5
Concomitant autoimmunity and late cancers in adult-onset immunodeficiency due to neutralizing anti-IFN-γ autoantibodies.
Tsai WT, Cheng CY, Sun HY, et al.
Frontiers in immunology 2025; (16()):1526439 doi:10.3389/fimmu.2025.1526439.
PMID: 40313931 - 6
Blockade Effects of Anti-Interferon- (IFN-) γ Autoantibodies on IFN-γ-Regulated Antimicrobial Immunity.
Krisnawati DI, Liu YC, Lee YJ, et al.
Journal of immunology research 2019; (2019()):1629258 doi:10.1155/2019/1629258.
PMID: 31275997 - 7
Determination of a distinguished interferon gamma epitope recognized by monoclonal antibody relating to autoantibody associated immunodeficiency.
Yasamut U, Wisitponchai T, Lee VS, et al.
Scientific reports 2022; (12(1)):7608 doi:10.1038/s41598-022-11774-9.
PMID: 35534543 - 8
Neutralizing Activity of Anti-interferon-γ Autoantibodies in Adult-Onset Immunodeficiency Is Associated With Their Binding Domains.
Yasamut U, Thongkum W, Moonmuang S, et al.
Frontiers in immunology 2019; (10()):1905 doi:10.3389/fimmu.2019.01905.
PMID: 31474987 - 9
Clinical outcome and laboratory markers for predicting disease activity in patients with disseminated opportunistic infections associated with anti-interferon-γ autoantibodies.
Angkasekwinai N, Suputtamongkol Y, Phoompoung P, et al.
PloS one 2019; (14(4)):e0215581 doi:10.1371/journal.pone.0215581.
PMID: 31022229 - 10
Anti-IFN-γ Autoantibody Syndrome Presenting with Disseminated Nontuberculous Mycobacteria Infections: A Case Series of Therapeutic Implications and Review of Literature.
Cheng B, Bajwa B, Choi S, et al.
Tropical medicine and infectious disease 2025; (10(7)) doi:10.3390/tropicalmed10070202.
PMID: 40711078 - 11
Recurrent disseminated Mycobacterium avium in a female patient from Thailand with anti-interferon-gamma autoantibodies: dilemma on treatment approach.
Zeitler K, Walter J, Khan F, Sriaroon C
BMJ case reports 2021; (14(1)) doi:10.1136/bcr-2020-237909.
PMID: 33509870 - 12
Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections.
Guo J, Ning XQ, Ding JY, et al.
The Journal of experimental medicine 2020; (217(12)) doi:10.1084/jem.20190502.
PMID: 32880631 - 13
Clinical Cognition and Practice in Anti-Interferon-γ Autoantibody-Associated Immunodeficiency Syndrome.
Liang S, Huang X, Liang X, et al.
Journal of clinical immunology 2026; (46(1)).
PMID: 42230416
This page provides educational information about Adult-Onset Immunodeficiency (AOID) and is not a substitute for professional medical advice. Always discuss your specific diagnosis and treatment plan with your immunologist or infectious disease specialist.
Get notified when new evidence is published on Adult-onset immunodeficiency with anti-interferon-gamma autoantibodies.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.